Sadanori Furudate
Overview
Explore the profile of Sadanori Furudate including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kawaguchi C, Ozawa M, Hidaka T, Murakami K, Ishikuro M, Ueno F, et al.
Allergol Int
. 2024 Oct;
PMID: 39426877
Background: Precise skin phenotypic data are indispensable in accurately diagnosing atopic dermatitis (AD). Therefore, this study examined the interobserver concordance for AD and non-AD diagnoses between two dermatologists. AD prevalence...
2.
Fujimura T, Ohuchi K, Ikawa T, Kambayashi Y, Amagai R, Furudate S, et al.
Hematol Oncol
. 2024 Jan;
42(1):e3244.
PMID: 38287534
Mycosis fungoides (MF) progresses slowly before advancing to skin tumors followed by lymph node and visceral involvement. Among MF progression, stage IIB is an initial time point of tumor formation...
3.
Mutoh T, Narita M, Nagai T, Furudate S, Taniuchi S, Kudo M, et al.
Arthritis Rheumatol
. 2023 Apr;
76(1):150-151.
PMID: 37096454
No abstract available.
4.
Fujimura T, Furudate S, Maekawa T, Kato H, Ito T, Matsushita S, et al.
Skin Health Dis
. 2023 Feb;
3(1):e180.
PMID: 36751323
Cutaneous angiosarcoma (CAS) is rare and most previous studies of CAS have been small case series, and randomized, phase II studies of CAS are limited. Since treatment options for CAS...
5.
Amagai R, Kambayashi Y, Ohuchi K, Furudate S, Hashimoto A, Asano Y, et al.
Dermatol Ther
. 2022 Sep;
35(11):e15858.
PMID: 36161437
Since the efficacy of mogamulizumab has been confirmed by a phase III, randomized study, mogamulizumab is one of the promising first-line therapies for advanced cutaneous T cell lymphoma (CTCL), though...
6.
Amagai M, Furudate S, Ohuchi K, Takahashi T, Yamazaki E, Chiba H, et al.
Case Rep Oncol
. 2022 Sep;
15(2):726-731.
PMID: 36157690
Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare variant of cutaneous T cell lymphoma (CTCL) characterized by CD30-expressing large atypical cells with kidney-shaped nuclei called hallmark cells. Since...
7.
Okuma T, Furudate S, Kambayashi Y, Hashimoto A, Aiba S, Fujimura T
J Dermatol
. 2021 May;
48(9):1419-1422.
PMID: 34002878
BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapeutic regimens for the treatment of advanced BRAF-mutant melanoma. Although the NCCN guideline for cutaneous melanoma...
8.
Muto Y, Fujimura T, Kambayashi Y, Ohuchi K, Amagai R, Okuma T, et al.
J Dermatol
. 2021 Jan;
48(3):e135-e136.
PMID: 33404105
No abstract available.
9.
Amagai R, Fujimura T, Muto Y, Kambayashi Y, Furudate S, Ohuchi K, et al.
Dermatol Ther
. 2020 Nov;
34(1):e14544.
PMID: 33190370
Various adverse events (AEs) have been reported to occur at a high rate in patients treated with dabrafenib plus trametinib (D + T) combination therapy. Among such AEs, the incidence...
10.
Fujimura T, Yoshino K, Kato H, Fujisawa Y, Nakamura Y, Yamamoto Y, et al.
J Dermatol
. 2020 Nov;
48(3):397-400.
PMID: 33179310
The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases...